

Marina Kaymakcalan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9554261/publications.pdf>

Version: 2024-02-01

15
papers

646
citations

932766

10
h-index

1058022

14
g-index

15
all docs

15
docs citations

15
times ranked

1330
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 372-381.	2.6	59
2	Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy+ Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 130-134.	0.9	15
3	Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 724-732.	0.9	34
4	Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , 2016, 122, 411-419.	2.0	27
5	QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>British Journal of Cancer</i> , 2015, 112, 296-305.	2.9	120
6	Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. <i>Cancer</i> , 2015, 121, 311-319.	2.0	165
7	Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2471-2479.	3.2	109
8	Diagnosis of Renal Cell Carcinoma. <i>Surgical Pathology Clinics</i> , 2015, 8, 657-662.	0.7	7
9	Adrenocortical carcinoma: The management of metastatic disease. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 123-132.	2.0	43
10	Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. <i>Annals of Oncology</i> , 2013, 24, 2092-2097.	0.6	31
11	Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. <i>British Journal of Cancer</i> , 2013, 108, 2478-2484.	2.9	31
12	Incidence and risk of infections in renal cell cancer (RCC) and non-RCC patients treated with everolimus and temsirolimus: A meta-analysis of randomized control trials.. <i>Journal of Clinical Oncology</i> , 2013, 31, 353-353.	0.8	3
13	Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 347-347.	0.8	1
14	Improving quality and safety of oncology patient care: Standardization of the post-clinic message triage process.. <i>Journal of Clinical Oncology</i> , 2013, 31, 163-163.	0.8	1
15	Developing and promoting evidence-based use of granulocyte colony stimulating factors (GCSF) in the palliative chemotherapy setting.. <i>Journal of Clinical Oncology</i> , 2013, 31, 172-172.	0.8	0